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hyperlipidemia was made concurrently with the index event in 28.5% and 16.8% of 
patients, respectively. CONCLUSIONS: High SrUA appears associated with increased 
risk of hypertension; very low SrUA may also be associated with hypertension risk. 
Approximately 20% of patients were diagnosed with hypertension or hyperlipidemia 
concurrently with the gout diagnosis, suggesting that gout was the event that initiated 
recognition of these comorbidities, and that, at least in this population, healthcare 
encounters may be symptomatically driven, with lower utilization for preventive care. 
Further evaluation of the relationship between SrUA and onset of hypertension and 
hyperlipidemia is warranted.
PMS11
Literature review - DoeS the CharaCterization of axiaL SPa 
Differ for BurDen of iLLneSS Between non-raDiograPhiC axiaL 
SPonDyLoarthritiS anD ankyLoSing SPonDyLitiS
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OBJECTIVES: Axial Spondyloarthritis (axSpA) is an inflammatory arthritic disease 
characterized by involvement of the spine, sacroiliac joints or both. Subtypes of 
axSpA include non-radiographic axial spondyloarthritis (nr-axSpA) without radio-
graphic sacroilitis confirmation, and ankylosing spondylitis (AS) with radiographic 
sacroilitis confirmation. These diseases are recognized within a spectrum of dis-
ease. Evidence suggests further stratification of nr-axSpA (e.g., MRI +/- or CRP +/-) 
may clarify the continuum of axSpA and improve clinical practice. Study objectives 
include illustrating burden of illness (BOI) similarities between the classic and fur-
ther stratified axSpA categories to suggest an improved diagnosis paradigm, and 
comparing BOI findings between nr-axSpA and AS subgroups to inform clinical 
practice. METHODS: English-language literature was searched systematically in 
Ovid SP, MEDLINE and EMBASE (2009–2014) for studies that described BOI charac-
teristics of nr-axSpA and AS including prevalence, disease activity, functioning, 
HRQL, productivity and medication utilization. PICO statement (population, inter-
vention, comparator and outcome) search terms were used. Supplementary records 
were obtained by searching American College of Rheumatology 2012 & 2013 and 
European League Against Rheumatism 2013 & 2014 scientific meeting abstracts. 
Additionally, electronic trial registries (e.g., clinicaltrials.gov), the USFDA website 
and article references were searched. RESULTS: 375 papers were retrieved and 
de-duplicated. Of the remaining 315 papers, 25 were selected per defined criteria. 
BOI in nr-axSpA and AS groups differed by gender, but were similar for all other 
categories (e.g., HRQL, functioning, productivity, etc.) indicating the two conditions 
pose a similar burden on patients. Nr-axSpA may be heterogeneous in presenta-
tion and follow a self-limiting or slowly-progressive disease course often seen in 
females (who may have lower inflammation activity). Although data for stratified 
groups (MRI+/-) within nr-axSpA was reported in one study, the evidence suggests 
similar BOI patterns. CONCLUSIONS: Future research should incorporate stratified 
nr-axSpA patient data for diagnostic comparisons and to inform clinical practice.
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review anD Meta-anaLySiS
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OBJECTIVES: Male osteoporosis is a common but neglected public health problem. 
This may be a result of limited data evaluating the efficacy of bisphosphonates 
for fracture prevention in males. This systematic review and meta-analysis study 
assessed the efficacy of bisphosphonates versus placebo in preventing fractures 
among males. METHODS: We searched PubMed/MEDLINE, Embase, Cochrane 
Clinical Trials Library, Clinicaltrials.gov, and Scopus. All randomized placebo-con-
trolled trials of alendronate, ibandronate, risedronate, or zoledronic acid with report-
ing fracture outcomes were assessed. The trials had to include males, be at least 
one year’s duration, and utilize the United States. Food and Drug Administration 
approved bisphosphonate dosing. The outcomes of interest included clinical ver-
tebral, morphometric vertebral, non-vertebral, hip, and any fracture. Fixed-effect 
models were used in both primary and subgroup meta-analyses. Publication bias 
was examined using funnel plots and Egger’s test. Meta-regressions were conducted 
to examine age, body mass index, bone mineral density T-scores, and proportion 
of male participants on the treatment effect. A sensitivity analysis using random 
effects assumption was also conducted. RESULTS: 43 studies were included in this 
meta-analysis; 19 of them reported separate fracture for males. Bisphosphonates 
had significant effects on reducing any fractures (Total population: Relative Risk 
(RR)= 0.63, 95% Confidence Interval (CI)= 0.50-0.79; Male population: RR= 0.58, 
95%CI= 0.36-0.85) and morphometric vertebral fractures (Total population: RR= 0.45, 
95%CI= 0.32-0.63; Male population: RR= 0.40, 95%CI= 0.22-0.73). There was very little 
evidence of heterogeneity (Total population: I2= 0.0%; Male population: I2= 11.9%-
15.3%). A visual inspection of the funnel plots and the Egger’s tests (Total popu-
lation: p= 0.119; Male population: p= 0.690) indicated no evidence of publication 
bias. Moreover, meta-regression showed effect size was unrelated to male pro-
portion. There was no significant superior treatment effect on other fracture out-
comes. CONCLUSIONS: Bisphosphonates significantly reduced vertebral fracture, 
and the effect was consistent regardless of male proportions. This supports use of 
bisphosphonates in males at risk for fracture.
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CoMPariSon of DiSeaSe StatuS anD outCoMeS of PatientS with 
rheuMatoiD arthritiS (ra) reCeiving aDaLiMuMaB or etanerCePt 
MonotheraPy in the uniteD StateS (uS)
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OBJECTIVES: To compare the disease status and outcomes of patients with RA 
receiving adalimumab and etanercept monotherapy in the US. METHODS: A 
PMS8
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in the BoDy During totaL joint arthroPLaSty
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OBJECTIVES: To quantify the frequency of and excess cost associated with for-
eign objects (e.g., surgical instruments and sponges) left in the body during total 
joint arthroplasty (TJA). METHODS: Data from the 2009-2012 National/Nationwide 
Inpatient Samples (NIS) were analyzed using descriptive (i.e., frequencies and 
means) and bivariate statistical methods (i.e., t-test, chi-square, and their non-
parametric equivalents). Patients that underwent TJA were identified through 
International Classification of Diseases, 9th Revision (ICD-9) procedure codes 81.51 
(hip TJA) and 81.54 (knee TJA). Patients with retained foreign objects were identi-
fied using ICD-9 external causes of injury code E871.0. NIS sample weights were 
used to generate national incidence estimates. Costs were estimated using the 
NIS’ charge-to-cost ratio for each hospital. All costs are reported in 2014 dollars 
using Consumer Price Index adjustment factors. We were only able to quantify the 
frequency and excess cost associated with foreign objects identified and reported 
during the peri-operative period (i.e., initial hospitalization). RESULTS: Included in 
the NIS were 761,225 patients that underwent TJA during the study period. Of these 
patients, only 44 (0.01%) had a retained foreign object (20 hip TJA and 24 knee TJA); 
however, TJA patients accounted for 4.5% of all surgical patients with a hospital-
reported retained object. These TJA patients underwent one additional procedure, 
on average, than those without a retained object (p< 0.0001). We estimate the total 
annual frequency of these events at 55 TJA patients. The estimated average excess 
cost of these avoidable adverse events is $4,950 (p= 0.0068). CONCLUSIONS: Despite 
considerable effort aimed at reducing the frequency in which foreign objects are 
inadvertently left in the body during surgery, these avoidable events continue to 
occur in TJA. While retained objects are rare events in TJA, these adverse events 
lead to excess cost and procedural burden for patients. Quality improvement efforts 
should continue unitl these events are eliminated.
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aSSoCiation Between SeDative-hyPnotiCS uSe anD faLLS in 
CoMMunity-DweLLing oLDer aDuLtS
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OBJECTIVES: In US, falls are the leading cause of injury deaths among older adults and 
rate of fall-related deaths has risen significantly over the past decade. Medications 
with sedative or hypnotic properties are known to increase fall risk, but are frequently 
prescribed to older adults. Thus, this study aims to provide more accurate estimate 
risk of falls in older adults taking sedative-hypnotic drugs by accounting for inad-
equately addressed variables (e.g., off-label sedative-hypnotic use, and potential 
confounders not found in claims data). METHODS: Study population were commu-
nity-dwelling older adults, age > 65, with Medicare Part A, B and D coverage. In addition 
to socio-demographic, health, behavioral, and environmental factors, beneficiaries’ 
past year fall and other fall-related information were collected from 2007 and 2009 fall 
supplements in Medicare Beneficiary Survey. Medication and comorbidity informa-
tion were collected from Medicare claims data. Sedative-hypnotic drugs consisted of 
antidepressants with sedating properties, benzodiazepines, and non-benzodiazepine 
hypnotics. Total drug day supply was calculated for each beneficiary to indirectly 
observe cumulative dose effect. Logistic regression was conducted to assess the asso-
ciation between sedative-hypnotic use and falls. RESULTS: A total 2,823 beneficiaries 
were included in the study. Proportion of those who reported past year fall were 33% 
for users and 21% for non-users (p< 0.01). When adjusted for socio-demographic and 
other covariates, sedative-hypnotic users were 1.5 times more likely to report a fall 
past year (OR 1.5, 1.2-2.0[PY1]); and 1.9 times for users with > 1 sedative-hypnotic 
drug class (1.9, 1.2-3.0). Only the users with < 90 day supply of sedative-hypnotics 
showed no increase in odds for past year fall. CONCLUSIONS: Sedative-hypnotic 
use was associated with increased risk of falls among older adults. Short-term use 
(< 90 day supply) of sedative-hypnotic drugs may provide a safer treatment strategy 
for this population. [PY1]95% confidence interval is provided for each odds ratio (OR)
PMS10
reLationShiP of SeruM uriC aCiD LeveLS with hyPertenSion anD 
hyPerLiPiDeMia in PatientS with gout
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OBJECTIVES: To use electronic health records (EHR) data to evaluate relationships 
of serum uric acid (SrUA) levels with hypertension and hyperlipidemia in patients 
with gout. METHODS: This retrospective study used de-identified EHR data from 
the Humedica database between 2010 and 2013. Patients were adults (≥ 18 years) 
with ≥ 2 ICD-9-CM diagnosis codes for gout ≥ 30 days apart (first diagnosis = index 
event), with ≥ 1 SrUA assessments, and ≥ 6 months pre- and ≥ 12 months post-index 
activity. Hypertension and hyperlipidemia were based on ICD-9 codes; patients with 
a hypertension or hyperlipidemia diagnosis during the 6-month pre-index period 
were excluded. Patients were stratified by SrUA quartiles: 0.01-4.0mg/dL (n= 2730), 
4.1-6.0mg/dL (n= 4349), 6.1-8.0mg/dL (n= 6136), and ≥ 8.1mg/dL (n= 5744). RESULTS: 
Patients were male (76.8%), white (81.1%) with mean±SD age of 60.5±14.1 years and 
mean±SD Charlson Comorbidity Index of 0.63±1.20. There were no significant differ-
ences across SrUA quartiles for proportions of patients diagnosed with hyperlipidemia 
12-months post-index, which ranged from 37.6% (4.1-6.0mg/dL) to 38.2% (0.01-4.0mg/
dL). In contrast, the ≥ 8.1mg/dL quartile had a significantly higher incidence of hyper-
tension, 60.3% (P< 0.001 versus all other quartiles), and the 0.01-4.0mg/dL quartile was 
significantly greater relative to the 4.1-6.0mg/dL quartile (56.1% vs 53.6%; P< 0.05) 
but similar to the 6.1-8.0mg/dL quartile (54.5%). The diagnosis of hypertension or 
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slightly higher disease burden and comorbidities. Factors influencing the observed 
patterns (including the choice of specific biologic for targeted patient profiles) may 
warrant further scrutiny to optimize therapeutic interventions and improve out-
comes.
PMS16
aSSeSSMent of the quaLity of Life in ChineSe MyaSthenia graviS 
PatientS
Zhang H.Y., Xie W.F., Zhang J.S., Yang G.L.
Liaoning University of Traditional Chinese Medicine, Shenyang, China
OBJECTIVES: Myasthenia Gravis (MG) is an auto immune disease of neuromuscular 
junction, which influences patients’ quality of life (QoL). Studies had showed MG 
patients with poor QoL, but there is no data in Chinese MG patients. METHODS: 
Consecutive MG patients are enrolled in three hospitals in Shenyang, China, from 
July, 2008 to June, 2010. Patients (14≤ age≤ 75 years) with class ‡T, ‡Ua, or ‡Ub MG 
according to Osserman’s classification are enrolled, and are separated into Ocular, 
Mild and Moderate groups. Familial MG, congenital MG and drug-induced MG 
are excluded. QoL is assessed by the SF-36 (rang: 0-100); severity of the disease is 
assessed by Chinese Score for MG (CSMG rang 12-60; higher scores worse weakness). 
Differences are tested using ANOVA and Kruskall-Wallis as appropriate. RESULTS: 
Analysis is based on 248 patients (male 110, 44%; age:46±18 year), of whom 27%, 
35% and 38% classified into Ocular, Mild and Moderated groups respectively. The 
disease history is 47±64 months (median 24). Fifty-nine patients have at least one 
comorbidity, and 71 with thymic hyperplasia, and 49 thymectomy. There is no sig-
nificant difference in demographic characteristics among three groups (P> 0.05), and 
no difference in disease history, comorbidity and treatment either. Ocular group has 
better QoL than Mild and Moderated groups: 64, 57, 51 for each group respectively 
(P= 0.000), and better weakness in CSMG scores: 21, 23, 26 respectively (P= 0.000). 
Significant differences is found in all the subscales of SF-36 among groups (P< 0.05), 
except for general health (P= 0.054), social functioning (P= 0.490), and role-emotional 
(P= 0.104). CONCLUSIONS: Our study reveals that Chinese MG patients have poor 
QoL, and Ocular MG patients have better QoL than those who are Mild and Moderate 
MG, and QoL is influence by the degree of muscle weakness.
PMS17
Long-terM DeCreaSe in gout fLare rateS aSSoCiateD with effeCtive 
urate Lowering theraPy
Kelton K.
Medical Decision Modeling, Indianapolis, IN, USA
OBJECTIVES: Previous clinical trials have demonstrated that gout patients who 
achieve the target serum urate acid (SUA) level ≤ 6 mg/dL with urate lowering ther-
apy (ULT) experience a reduction in the frequency of gout flares over time. This find-
ing has not been fully exploited in pharmacoeconomic models of ULTs that associate 
constant flare rates with SUA levels. The objective of this study was to quantify the 
long-term rate of decrease in flare frequency among subjects who achieved the tar-
get SUA level in the fEbuXostat/allopurinol Comparative Extension Long-term study 
(EXCEL). METHODS: The EXCEL trial reported the proportion of subjects experienc-
ing ≥ 1 gout flare requiring treatment by two-month intervals. Binomial regression 
was used to fit Gompertz and Weibull survival models to the observations at least 
6 months after baseline, pooled across treatment arms. Model fit was assessed 
by a chi-square test of the model deviance. RESULTS: The goodness of fit test for 
the Gompertz survival model indicated that the model provides an adequate fit to 
the data (model deviance = 14.14 with 15 degrees of freedom; p= .5146). However, 
the goodness of fit test for the Weibull survival model indicated an inadequate 
fit to the data (model deviance = 55.01 with 15 degrees of freedom; p< .0001). The 
maximum likelihood estimate of the shape parameter of the Gompertz survival 
model is -0.0906, where time is measured in months. CONCLUSIONS: The long-
term (≥ 6 months after baseline) gout flare results reported in the EXCEL trial can 
be adequately modeled by a Gompertz survival model, which estimates that the 
gout flare rate decreased by 9.06% per month for subjects who achieved the target 
SUA level of ≤ 6 mg/dL. The results of this analysis may be useful for modeling the 
long-term clinical and economic outcomes of ULTs in patients with gout.
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eLDerLy PatientS with enD-Stage renaL DiSeaSe: a retroSPeCtive 
Cohort StuDy
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OBJECTIVES: Evidence supporting the use of anti-osteoporosis (AO) medications 
(AOMs) for preventing fracture among elderly patients with end-stage renal disease 
(ESRD) was scarce. This study evaluated the benefits of AOMs in fracture preven-
tion for elderly patients with ESRD. METHODS: Using 1997-2008 Taiwan’s National 
Health Insurance research database, we identified incident chronic dialysis patients 
with concomitant diagnosis of osteoporosis who had received AOMs during the 
year before dialysis between 1998 and 2007; the AOMs included salmon calcitonin, 
alendronate, zoledronate, raloxifene, and teriparatide. Following the inception of 
dialysis, patients who continued AOMs were categorized into AO treated cohort 
and those who ceased using AOMs were AO untreated cohort. Study outcomes were 
defined as hospitalizations due to hip or vertebral fracture during the follow-up 
period. RESULTS: We identified 490 patients receiving AOMs during the year before 
dialysis. The mean age of AO untreated cohort and AO treated cohort were 74.40 and 
71.64. Fracture hazard risk (HR) in the AO treated cohort was not significantly lower 
than the AO untreated cohort, either unadjusted (HR = 1.02, 95%CI = 0.40-2.62, p = 
0.96) or adjusted (HR = 0.92, 95%CI = 0.30-2.82, p = 0.89). Further analysis in female 
patients resulted in a similar finding. CONCLUSIONS: This study found that use 
of AOMs was not associated with a reduction of fracture risk in elderly chronically 
dialyzed patients.
retrospective medical chart-review of RA patients was conducted to collect de-
identified data for those recently treated with a biologic as part of usual care. 
Physicians (rheumatologists) were screened for duration of practice (3-30yrs) and 
patient volume (incl. > 5 RA biologic patients/month) and recruited from a large 
panel to be geographically representative. Eligible patient charts (≥ 3) were randomly 
selected from a sample of patients visiting each center/practice during the screen-
ing period. Physicians abstracted patient diagnosis, treatment patterns/dynamics 
and patient symptomatology/disease status/outcomes. Patients on adalimumab/
etanercept monotherapy were analyzed. RESULTS: 169 eligible RA patient charts 
were abstracted; 43 on adalimumab (female: 63%, age: 51.7 yrs, average months on 
adalimumab: 39.5, 98% on first biologic) and 63 on etanercept (female: 78%, age: 49.3 
yrs, average months on etanercept: 40.2, 87% on first biologic). Top-3 comorbidites 
(adalimumab vs. etanercept) were obesity: 21% vs. 10%, dyslipidemia: 21% vs. 6% 
and depression/anxiety: 12% vs. 11%. Among patients with available data, latest lab 
measures documented were (adalimumab vs. etanercept): ESR: 26.4 mm/h vs. 23.4 
mm/h, CRP: 2.6 mg/dl vs. 1.7 mg/dl, rheumatoid factor-positive: 84% vs. 73%, and 
anti-CPP-positive: 65% vs. 59%. Latest disease severity measures documented were 
(adalimumab vs. etanercept): Swollen Joint Counts: 1.7 vs. 1.6, Tender Joint Counts: 
2.5 vs. 2.8, and VAS score: 2.4 vs. 2.2. CONCLUSIONS: RA patients on adalimumab 
monotherapy were slightly older and had a lower percentage of female patients than 
those on etanercept. Most (> 85%) were on their first biologic. The adalimumab group 
appeared to have a slightly higher disease burden and comorbidities. Factors influ-
encing the observed patterns (including the choice of specific biologic for targeted 
patient profiles) may warrant further scrutiny to optimize therapeutic interventions 
and improve outcomes.
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effiCaCy of tofaCitiniB in CoMBination with Methotrexate 
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Methotrexate: overview of SySteMatiC review
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1Pfizer SAS, Bogota, Colombia, 2Universidad Nacional, Bogota, Colombia
OBJECTIVES: Tofacitinib is a new oral drug which has demonstrated efficacy and 
safety in pivotal clinical trials. This study sough to assess the efficacy of tofaci-
tinib in combination with methotrexate compared with biological DMARDs in 
combination with methotrexate, in rheumatoid arthritis (RA) patients with an 
inadequate response to methotrexate. METHODS: We performed an analysis of 
systematic review published in the last five years that assessed biological DMARDs 
(Adalimumab, certolizumab, infliximab, etanercept, golimumab, tocilizumab, rituxi-
mab and abatacept) or tofacitinib to treatment of RA after inadequate response 
to methotrexate. The search was realized in the database of Medline, EMBASE, 
Cochrane, LILACS, DARE and HTA. The data collection was realized by two research-
ers independently. Clinical trials that had been included in the systematic reviews 
were extracted and evaluated their methodological quality with checklist Cochrane. 
With mixed treatment comparison, the effectiveness between biological DMARDs 
and tofacitinib was compared using methotrexate as a common comparator. The 
outcomes considered in terms of effectiveness were improvement rates by ACR20, 
ACR50, ACR70 and HAQ criteria at 12 and 24 weeks. In order to evaluate the impact 
of heterogeneity, we performed analysis of sensibility and subgroups. RESULTS: 
27 systematic reviews were included of which 30 clinical trials were assessed and 
analyzed. The indirect comparison showed that tofacitinib has similar efficacy in 
comparison to biological DMARDs in ACR20, ACR50, ACR70 and HAQ at 12 and 24 
weeks. However, certolizumab displayed better response that tofacitinib in ACR20 
at 12 weeks (OR 0.373 IC 95% 0.201 – 0.615). The sensitivity and subgroup analyses 
by the design of clinical trials, years of disease and number of swollen joint showed 
consistent results. CONCLUSIONS: The mixed treatment comparison indicated that 
tofacitinib is similar in terms of efficacy than biological DMARDs in RA patients with 
an inadequate response to methotrexate.
PMS15
CoMPariSon of DiSeaSe StatuS anD outCoMeS of PatientS with 
PSoriatiC arthritiS (PSa) reCeiving aDaLiMuMaB or etanerCePt 
MonotheraPy in the uniteD StateS (uS)
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OBJECTIVES: To compare the disease status and outcomes of patients with PsA 
receiving adalimumab and etanercept monotherapy in the US. METHODS: A retro-
spective medical chart-review of PsA patients was conducted to collect de-identified 
data for those recently treated with a biologic as part of usual care. Physicians 
(rheumatologists) were screened for duration of practice (3-30yrs) and patient 
volume (incl. > 5 PsA biologic patients/month) and recruited from a large panel 
to be geographically representative. Eligible patient charts (≥ 3) were randomly 
selected from a sample of patients visiting each center/practice during the screen-
ing period. Physicians abstracted patient diagnosis, treatment patterns/dynamics 
and patient symptomatology/disease status/outcomes. Patients on adalimumab/
etanercept monotherapy were analyzed. RESULTS: 84 eligible PsA patient charts 
were abstracted; 37 on adalimumab (male: 54%, age: 46.5 yrs, average months on 
adalimumab: 28.2, 92% on first biologic) and 29 on etanercept (male: 62%, age: 42.3 
yrs, average months on etanercept: 32.2, 100% on first biologic). Top-5 comorbid-
ites (adalimumab vs. etanercept) were obesity: 24% vs. 17%, dyslipidemia: 8% vs. 
7%, diabetes: 8% vs. 3%, kidney disease: 8% vs. 0%, migraine: 3% vs. 3%. Among 
patients with available data, latest lab measures documented were (adalimumab 
vs. etanercept): ESR: 28.0 mm/h vs. 15.8 mm/h and CRP: 3.9 mg/dl vs. 2.3 mg/dl. 
Latest disease severity measures documented were (adalimumab vs. etanercept): 
Swollen Joint Counts: 1.8 vs. 1.1, Tender Joint Counts: 2.6 vs. 3.9, and HAQ rating: 0.7 
vs. 0.3. CONCLUSIONS: PsA patients on adalimumab monotherapy were slightly 
older and on adalimumab for fewer average months than patients on etanercept. 
Most (> 90%) were on their first biologic. The adalimumab group appeared to have a 
